It may look good on paper, but the 60% upswing in Perigrine Pharmaceuticals (PPHM +50%) this morning is a paltry move compared to yesterdays 75% cratering the shares took after reporting that previously released results from a midstage cancer drug study aren't reliable because of a third-party error. The big relative move off the bottom is largely a "dead cat bounce" when you consider that it still remains down 67% from Friday's close.
It may look good on paper, but the 60% upswing in Perigrine Pharmaceuticals (PPHM +50%) this...
From other sites
at CNBC.com (Jul 14, 2014)
at CNBC.com (Jul 11, 2013)
at CNBC.com (Mar 12, 2013)
at CNBC.com (Mar 5, 2013)
at CNBC.com (Sep 24, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs